CollaGenex Pharmaceuticals, Inc.

Positive outcome reported on phase II study evaluating Metastat

Published in Physician Law Weekly, June 2nd, 2004

CollaGenex Pharmaceuticals, Inc., (CGPI) announced the interim results of a phase II multicenter, open label and randomized clinical study evaluating the safety and efficacy of its investigational product, Metastat (Col-3), for the treatment of HIV-related Kaposi sarcoma.

This phase II study is conducted under a CRADA between CollaGenex and the National Cancer Institute (NCI). The principal investigator is Bruce Dezube, MD, of Beth Israel Deaconess Medical Center at the Harvard Medical School. Seventy five patients were randomized to receive Col-3 at a dose of either 50 mg or 100 mg per day. The study is still ongoing with 12 patients in the low dose group and 10...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Physician Law Weekly

Source: Physician Law Weekly (2004-06-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry